Caricamento...

Teriflunomide in Patients with Relapsing–Remitting Forms of Multiple Sclerosis

Teriflunomide is a once-daily oral agent that has been licensed in the EU since August 2013 for the treatment of adult patients with relapsing–remitting multiple sclerosis (RRMS). More recently (September 2014), the EU summary of product characteristics (SmPC) was updated to include data from patien...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:CNS Drugs
Autori principali: Chan, Andrew, de Seze, Jérôme, Comabella, Manuel
Natura: Artigo
Lingua:Inglês
Pubblicazione: Springer International Publishing 2016
Soggetti:
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC4733135/
https://ncbi.nlm.nih.gov/pubmed/26758290
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40263-015-0299-y
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !